EA007415B1 - Пирролопиримидины как ингибиторы протеинкиназы - Google Patents
Пирролопиримидины как ингибиторы протеинкиназы Download PDFInfo
- Publication number
- EA007415B1 EA007415B1 EA200400073A EA200400073A EA007415B1 EA 007415 B1 EA007415 B1 EA 007415B1 EA 200400073 A EA200400073 A EA 200400073A EA 200400073 A EA200400073 A EA 200400073A EA 007415 B1 EA007415 B1 EA 007415B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- compound according
- effective amount
- compounds
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200400073A1 EA200400073A1 (ru) | 2004-08-26 |
EA007415B1 true EA007415B1 (ru) | 2006-10-27 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400073A EA007415B1 (ru) | 2001-06-23 | 2002-06-21 | Пирролопиримидины как ингибиторы протеинкиназы |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (et) |
JP (1) | JP4344607B2 (et) |
CN (1) | CN1294135C (et) |
AU (1) | AU2002314325B8 (et) |
BR (1) | BR0210652A (et) |
CA (1) | CA2451932C (et) |
CZ (1) | CZ20033443A3 (et) |
EA (1) | EA007415B1 (et) |
EC (1) | ECSP034922A (et) |
EE (1) | EE05432B1 (et) |
GB (1) | GB0115393D0 (et) |
HU (1) | HUP0400300A3 (et) |
ME (1) | MEP19308A (et) |
NZ (1) | NZ529766A (et) |
OA (1) | OA12632A (et) |
PL (1) | PL374096A1 (et) |
RS (1) | RS51698B (et) |
SK (1) | SK15882003A3 (et) |
TN (1) | TNSN03144A1 (et) |
TR (1) | TR200302242T2 (et) |
UA (1) | UA76760C2 (et) |
WO (1) | WO2003000695A1 (et) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962629B2 (en) | 2008-06-10 | 2015-02-24 | Abbvie Inc. | Tricyclic compounds |
US9879018B2 (en) | 2015-10-16 | 2018-01-30 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof |
USRE47221E1 (en) | 2009-12-01 | 2019-02-05 | Abbvie Inc. | Tricyclic compounds |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
WO2005047289A1 (en) * | 2003-11-17 | 2005-05-26 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
JP2007512316A (ja) * | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
TWI468162B (zh) | 2005-12-13 | 2015-01-11 | 英塞特公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶 |
BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
SG10201509887UA (en) | 2007-06-13 | 2016-01-28 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8349847B2 (en) | 2008-01-11 | 2013-01-08 | Durga Prasad Konakanchi | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
PL2877467T3 (pl) | 2012-07-26 | 2017-08-31 | Glaxo Group Limited | 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112015010663B1 (pt) | 2012-11-15 | 2022-12-06 | Incyte Holdings Corporation | Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo |
CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
CN105026393A (zh) | 2013-03-13 | 2015-11-04 | 艾伯维公司 | Cdk9激酶抑制剂 |
JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
WO2014160028A1 (en) * | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
TW201446763A (zh) | 2013-03-14 | 2014-12-16 | Abbvie Inc | 吡咯并[2,3-b]吡啶cdk9激酶抑制劑 |
CA2905935A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
RS60469B1 (sr) | 2013-08-07 | 2020-07-31 | Incyte Corp | Dozni oblici sa produženim oslobađanjem za jak1 inhibitor |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
AU2018230500B2 (en) | 2017-03-09 | 2024-03-07 | Abbvie Inc. | Methods of treating Crohn's disease and ulcerative colitis |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
DK3860998T3 (da) | 2018-10-05 | 2024-03-25 | Annapurna Bio Inc | Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023613A1 (en) * | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2000017202A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
US6140317A (en) * | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 EE EEP200400003A patent/EE05432B1/et not_active IP Right Cessation
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en active Application Filing
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140317A (en) * | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
WO1998023613A1 (en) * | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2000017202A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
Non-Patent Citations (1)
Title |
---|
D. BERGSTROM ET AL.: "Palladium-mediated synthesis of C-5 pyrimidine nucleoside thioethers from disulfides and mercurinucleosides" J. ORG. CHEM., vol. 56, no. 19, 1991, pages 5598-5602, XP002214295 * Scheme III * * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9365579B2 (en) | 2008-06-10 | 2016-06-14 | Abbvie Inc. | Tricyclic compounds |
US8962629B2 (en) | 2008-06-10 | 2015-02-24 | Abbvie Inc. | Tricyclic compounds |
USRE47221E1 (en) | 2009-12-01 | 2019-02-05 | Abbvie Inc. | Tricyclic compounds |
US11186584B2 (en) | 2015-10-16 | 2021-11-30 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10344036B2 (en) | 2015-10-16 | 2019-07-09 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
US9963459B1 (en) | 2015-10-16 | 2018-05-08 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
US10017517B2 (en) | 2015-10-16 | 2018-07-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluorethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11198697B1 (en) | 2015-10-16 | 2021-12-14 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10202393B2 (en) | 2015-10-16 | 2019-02-12 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10202394B2 (en) | 2015-10-16 | 2019-02-12 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10519164B2 (en) | 2015-10-16 | 2019-12-31 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10597400B2 (en) | 2015-10-16 | 2020-03-24 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
US10730883B2 (en) | 2015-10-16 | 2020-08-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10981923B2 (en) | 2015-10-16 | 2021-04-20 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10981924B2 (en) | 2015-10-16 | 2021-04-20 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10995095B2 (en) | 2015-10-16 | 2021-05-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
US9879018B2 (en) | 2015-10-16 | 2018-01-30 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof |
US9879019B2 (en) | 2015-10-16 | 2018-01-30 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US9951080B2 (en) | 2015-10-16 | 2018-04-24 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11535625B2 (en) | 2015-10-16 | 2022-12-27 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11535624B2 (en) | 2015-10-16 | 2022-12-27 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11535626B2 (en) | 2015-10-16 | 2022-12-27 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
US11661425B2 (en) | 2015-10-16 | 2023-05-30 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11680069B2 (en) | 2015-10-16 | 2023-06-20 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11718627B2 (en) | 2015-10-16 | 2023-08-08 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11767326B2 (en) | 2015-10-16 | 2023-09-26 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773105B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11780847B1 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11787815B1 (en) | 2015-10-16 | 2023-10-17 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11795175B2 (en) | 2015-10-16 | 2023-10-24 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11976077B2 (en) | 2015-10-16 | 2024-05-07 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof |
Also Published As
Publication number | Publication date |
---|---|
CA2451932C (en) | 2009-12-29 |
OA12632A (en) | 2006-06-14 |
HUP0400300A3 (en) | 2010-12-28 |
ECSP034922A (es) | 2004-04-28 |
JP4344607B2 (ja) | 2009-10-14 |
EA200400073A1 (ru) | 2004-08-26 |
CZ20033443A3 (en) | 2004-03-17 |
GB0115393D0 (en) | 2001-08-15 |
EP1404676A1 (en) | 2004-04-07 |
BR0210652A (pt) | 2004-08-10 |
AU2002314325B2 (en) | 2009-01-08 |
CN1294135C (zh) | 2007-01-10 |
TR200302242T2 (tr) | 2004-12-21 |
RS51698B (en) | 2011-10-31 |
WO2003000695A8 (en) | 2004-03-11 |
SK15882003A3 (sk) | 2004-07-07 |
HUP0400300A2 (en) | 2007-08-28 |
JP2005508300A (ja) | 2005-03-31 |
MEP19308A (en) | 2010-06-10 |
TNSN03144A1 (en) | 2005-12-23 |
NZ529766A (en) | 2008-11-28 |
RS99203A (en) | 2006-12-15 |
EE05432B1 (et) | 2011-06-15 |
UA76760C2 (uk) | 2006-09-15 |
CN1518552A (zh) | 2004-08-04 |
CA2451932A1 (en) | 2003-01-03 |
WO2003000695A1 (en) | 2003-01-03 |
EE200400003A (et) | 2004-02-16 |
PL374096A1 (en) | 2005-09-19 |
AU2002314325B8 (en) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA007415B1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
AU2002314325A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
US7259154B2 (en) | Pyrrolopyrimidines | |
EP2496559B1 (en) | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline and their use as hsd 1 inhibitors | |
EP1180105B1 (en) | Substituted aza-oxindole derivatives | |
CZ301751B6 (cs) | Bicyklický pyrrolový derivát, farmaceutická kompozice obsahující tento derivát, tato kompozice pro použití pri lécení a použití uvedeného derivátu pri výrobe léciva | |
EA016815B1 (ru) | 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции | |
TW201319067A (zh) | 三唑并吡啶化合物 | |
EP3066099B1 (en) | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | |
Wang et al. | Investigation on the 1, 6-naphthyridine motif: Discovery and SAR study of 1 H-imidazo [4, 5-h][1, 6] naphthyridin-2 (3 H)-one-based c-Met kinase inhibitors | |
JP4871474B2 (ja) | アザインドール | |
WO2021239727A1 (en) | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer | |
CN111699188B (zh) | [1,2,4]三唑并[4,3-a]吡嗪-8-酮衍生物 | |
AU2020380828A1 (en) | WDR5 inhibitors and modulators | |
US20070249590A1 (en) | Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders | |
EA028824B1 (ru) | Хинолиновые производные как ингибиторы фермента pde10a | |
WO2021147790A1 (zh) | 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途 | |
WO2023001133A1 (zh) | Prmt5抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |